siRNA-based nanotherapeutics targeting tumor cells downregulate immune-checkpoint proteins (e.g., PD-L1), so-called “don't-eat-me” signals (e.g., CD47), and anti-inflammatory cytokines to induce an antitumor immune response 202. The gene discussed is CD274; the disease is neoplasm.